Literature DB >> 9885772

The role of factors that regulate the synthesis and secretion of very-low-density lipoprotein by hepatocytes.

T M Mason1.   

Abstract

Lipoproteins are particles that contribute to overall metabolic homeostasis by transporting hydrophobic lipids in the blood plasma to and from different tissues in the body. Very-low-density lipoprotein (VLDL) is the principal vehicle for the transport of endogenous triglyceride (TG), and, ultimately, through its metabolic product, low-density lipoprotein (LDL), of cholesterol as well. It is synthesized mainly in hepatocytes, with small amounts also being produced by enterocytes in the fasting state. The mechanism of VLDL assembly is complex and is regulated at different levels by a variety of factors. The main structural protein of VLDL is called apolipoprotein B-100 (Apo B). Apo B formation and degradation therefore represent two major points of regulation of VLDL secretion. Hepatic levels of lipids such as phosphatidylcholine (PC), cholesteryl ester (CE), fatty acids (FA), and TG also affect VLDL synthesis. There are different views as to the specific mechanism by which each lipid class affects VLDL particle formation. In general, PC appears to promote the translocation of apo B from the cytosol to the lumen of the endoplasmic reticulum, a step that is crucial in the early stages of VLDL assembly. Apo B degradation is suppressed, and therefore VLDL secretion is enhanced, in the presence of elevated CE levels. For TG to be incorporated into the lipoprotein, it requires the action of a protein called microsomal triglyceride transfer protein (MTP). MTP might have a preference for TG comprised of FA with a certain degree of saturation. It becomes apparent that changes in diet that are accompanied by variations in the type of fats that are ingested affect VLDL formation and secretion. Regulation also occurs post-prandially in response to elevations in plasma insulin levels. Acute elevations in insulin inhibit VLDL secretion by promoting the degradation of apo B. This action is consistent with insulin's anabolic properties as it allows for the hepatic storage of lipid rather than for its distribution in VLDL to other tissues for fuel. Many studies have attempted to unravel the mechanisms of VLDL formation and secretion. The fact that so many factors are involved complicates the issue. The purpose of this article is to describe the relationship between different factors involved in VLDL assembly and secretion so that a better understanding of its metabolic regulation may be achieved.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9885772     DOI: 10.1080/10408369891234246

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  21 in total

Review 1.  Statins in type 2 diabetes mellitus: target on lipids and vascular wall function.

Authors:  M A van de Ree; F V van Venrooij; A E Meinders; I J A M Jonkers; I Berk-Planken; M V Huisman
Journal:  Neth Heart J       Date:  2003-03       Impact factor: 2.380

Review 2.  Lipid metabolism in pregnancy and its consequences in the fetus and newborn.

Authors:  Emilio Herrera
Journal:  Endocrine       Date:  2002-10       Impact factor: 3.633

3.  Mature VLDL triggers the biogenesis of a distinct vesicle from the trans-Golgi network for its export to the plasma membrane.

Authors:  Tanvir Hossain; Aladdin Riad; Shaila Siddiqi; Sampath Parthasarathy; Shadab A Siddiqi
Journal:  Biochem J       Date:  2014-04-01       Impact factor: 3.857

4.  Choline supply of preterm infants: assessment of dietary intake and pathophysiological considerations.

Authors:  Wolfgang Bernhard; Anna Full; Jörg Arand; Christoph Maas; Christian F Poets; Axel R Franz
Journal:  Eur J Nutr       Date:  2012-09-09       Impact factor: 5.614

5.  The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment.

Authors:  Jennifer A Smith; Donna K Arnett; Reagan J Kelly; Jose M Ordovas; Yan V Sun; Paul N Hopkins; James E Hixson; Robert J Straka; James M Peacock; Sharon L R Kardia
Journal:  Eur J Hum Genet       Date:  2008-01-23       Impact factor: 4.246

Review 6.  From whole body to cellular models of hepatic triglyceride metabolism: man has got to know his limitations.

Authors:  Charlotte J Green; Camilla Pramfalk; Karl J Morten; Leanne Hodson
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-10-28       Impact factor: 4.310

7.  PREP1 deficiency downregulates hepatic lipogenesis and attenuates steatohepatitis in mice.

Authors:  Francesco Oriente; Serena Cabaro; Antonietta Liotti; Michele Longo; Luca Parrillo; Teresa Bruna Pagano; Gregory Alexander Raciti; Dmitry Penkov; Orlando Paciello; Claudia Miele; Pietro Formisano; Francesco Blasi; Francesco Beguinot
Journal:  Diabetologia       Date:  2013-09-20       Impact factor: 10.122

8.  Characterization of lipid metabolism in a novel immortalized human hepatocyte cell line.

Authors:  Charlotte J Green; Deborah Johnson; Harsh D Amin; Pamela Sivathondan; Michael A Silva; Lai Mun Wang; Lara Stevanato; Catriona A McNeil; Erik A Miljan; John D Sinden; Karl J Morten; Leanne Hodson
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-06-30       Impact factor: 4.310

9.  Systematic analysis of the regulatory functions of microRNAs in chicken hepatic lipid metabolism.

Authors:  Hong Li; Zheng Ma; Lijuan Jia; Yanmin Li; Chunlin Xu; Taian Wang; Ruili Han; Ruirui Jiang; Zhuanjian Li; Guirong Sun; Xiangtao Kang; Xiaojun Liu
Journal:  Sci Rep       Date:  2016-08-18       Impact factor: 4.379

10.  All-In-One: Advanced preparation of Human Parenchymal and Non-Parenchymal Liver Cells.

Authors:  Melanie Werner; Sabrina Driftmann; Kathrin Kleinehr; Gernot M Kaiser; Zotlan Mathé; Juergen-Walter Treckmann; Andreas Paul; Kathrin Skibbe; Joerg Timm; Ali Canbay; Guido Gerken; Joerg F Schlaak; Ruth Broering
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.